NASDAQ:AKTS Aktis Oncology Q4 2025 Earnings Results & Report $16.01 -0.48 (-2.91%) Closing price 04:00 PM EasternExtended Trading$16.02 +0.00 (+0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aktis Oncology reported Q4 2025 earnings on March 30, 2026. The company reported EPS of -$18.17, while revenue was $1.87 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 30, 2026TimeAfter Market ClosesConference Call8:00 AM ET Aktis Oncology EPS ResultsActual EPS-$18.17Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersAktis Oncology Revenue ResultsActual Revenue$1.87 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAktis Oncology's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Aktis Oncology Q4 2025 Earnings FAQ Did Aktis Oncology beat earnings estimates for Q4 2025? Aktis Oncology (NASDAQ:AKTS) reported earnings of -$18.17 per share for Q4 2025. The report was announced on Monday, March 30, 2026. What was Aktis Oncology's revenue for Q4 2025? Aktis Oncology reported revenue of $1.87 million for Q4 2025. When is Aktis Oncology's next earnings date? Aktis Oncology's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aktis Oncology on the company's earnings history page. Aktis Oncology Earnings HeadlinesAktis Oncology: Padcev Is Building The Market It WantsOctober 14 at 4:31 PM | seekingalpha.comAktis Oncology, Inc. (AKTS)October 8, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)Wedbush Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS)October 7, 2026 | theglobeandmail.comOncocyte (NASDAQ:IMDX) & Aktis Oncology (NASDAQ:AKTS) Head-To-Head SurveyOctober 5, 2026 | americanbankingnews.comAktis Oncology (NASDAQ:AKTS) Earns "Outperform" Rating from WedbushOctober 4, 2026 | americanbankingnews.comSee More Aktis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aktis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aktis Oncology and other key companies, straight to your email. Email Address About Aktis OncologyAktis Oncology (NASDAQ:AKTS), Inc. is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue. The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors. Aktis Oncology is advancing a pipeline of investigational programs intended to address solid tumors and other cancers where targeted radiotherapy may offer a therapeutic benefit. As an early-stage biotechnology company, Aktis Oncology’s products remain in development and have not been broadly commercialized. Information about its clinical pipeline, corporate leadership, and geographic operations may change as the company progresses its research and development programs.View Aktis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
